Biotech Values

[jbog]

"Based on assumptions regarding healthcare trends, industry positioning and the overall environment, the company is targeting annual earnings per share growth of 10 per cent to 20 per cent for the next several years," St Louis-based Express said in a release announcing its quarterly results.

There nothing about indefinitely in this article? but I wouldn't find it hard to swallow if you consider the pricing structure of drugs.